drugset
drugset / Trial / NCT03802227

A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.

NCT03802227 ↗

Phase 1 Terminated 8 enrolled Nektar Therapeutics
RandomizedParallel-groupTriple-blindBasic science

Summary

The main purpose of this study is to evaluate the effect of NKTR-181 on brain activity in healthy, non-physically dependent recreational opioid users. This study will last about 88 days for each participant.

Timeline

Start
2018-10-22
Primary completion
2019-12-17
Completion
2020-01-03

Outcome

Outcome not reported

Stopped (Business): “Sponsor Decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject OXYCODEGOL Small molecule 400 mg —
Subject Oxycodone Other / unclassified 40 mg —

Indications

No indication recorded.